Why Mycardium

In order to harness the know-how and launch to market globally, Mycardium was formed in April 2022 and has rapidly developed to become a world leading innovator for cardiac imaging and core labs services. The unique blend of clinicians, academics, developers and scientists have combined to deliver our superhuman AI for measuring the heart, and a clinically led core lab service that offers far more than the what is traditionally expected. From study design to the ability to deliver leaner drug trials with less patients, potentially showing positive markers more quickly, pharma and biotechs benefit from our precision and accuracy. We have grown to become an international company based both in the UK and North America and continue to evolve with a relentless focus on quality, both in terms of products, services and after sales support.